리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 11월
페이지 정보:영문 262 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 인간용 백신 시장은 2030년까지 714억 달러에 달할 전망
2024년에 469억 달러로 추정되는 세계의 인간용 백신 시장은 2024-2030년의 분석 기간에 CAGR 7.3%로 성장하며, 2030년까지 714억 달러에 달할 것으로 예측되고 있습니다. 이 리포트에서 분석 대상 부문의 하나인 근육내·피하 투여는 7.8%의 CAGR을 기록하며, 분석 기간 종료까지 587억 달러에 달할 것으로 예측됩니다. 경구 투여 부문의 성장률은 분석 기간에 5.3%의 CAGR로 추정되고 있습니다.
미국 시장은 124억 달러로 추정되는 한편, 중국은 11.7%의 CAGR로 성장할 것으로 예측됩니다.
미국의 인간용 백신 시장은 2024년에 124억 달러로 추정되고 있습니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 11.7%로 추이하며, 2030년까지 168억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장 분석으로는 일본과 캐나다를 들 수 있으며, 각각 분석 기간 중 2.6%와 7.5%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 약 4.1%의 CAGR로 성장할 것으로 예측됩니다.
세계의 인간용 백신 시장 - 주요 시장 동향과 촉진요인의 개요
인간 백신의 힘: 현대 의학의 초석
인체 백신은 공중보건의 가장 큰 성과 중 하나이며, 면역체계가 병원체를 인식하고 싸우도록 훈련시켜 수많은 감염성 질환으로부터 보호해줍니다. 병원체를 모방한 항원으로 구성된 백신은 면역체계가 질병과 신속하고 효과적으로 싸울 수 있도록 준비하는 데 매우 중요합니다. 이 메커니즘을 통해 천연두, 소아마비 등 수많은 생명을 위협하는 질병을 성공적으로 퇴치 및 감소시켰으며, 전 세계에서 발병률과 사망률을 크게 낮추었습니다. 백신은 개인을 보호할 뿐만 아니라 집단 면역 형성에 기여하여 지역사회 전체의 감염 확산을 방지하고, 나아가 전 세계 공중보건 확보에 기여하고 있습니다.
새로운 영역으로의 도전: 백신의 효능과 안전성을 높이는 혁신
백신 기술은 끊임없이 진화하고 있으며, 더 나은 보호 효과와 안전성을 약속하는 새로운 방법을 도입하고 있습니다. 전통적 백신 전략은 효과적이지만, mRNA 백신과 재조합 기술과 같은 최첨단 접근법을 통해 강화되고 있습니다. 이러한 혁신 기술은 특히 COVID-19 팬데믹과 같은 세계 도전에 신속하게 대응하는 데 있으며, 정밀한 타겟팅과 빠른 확장성을 제공하는 데 중요한 역할을 할 수 있습니다. 또한 보조제의 개발과 개선된 전달 시스템은 백신의 효능에 혁명을 일으키고 있으며, 보다 복잡한 질병과의 싸움의 지평을 넓히고 다양한 집단에 맞는 예방접종을 실현할 수 있도록 하고 있습니다.
세계 백신 산업을 재편하는 새로운 동향
세계적인 인구 통계와 기술 동향이 백신 산업을 재편하고 있습니다. 국제 이동 증가와 도시화는 감염병 전파의 위험을 증가시키고 효과적인 예방접종 프로그램의 필요성을 증폭시키고 있습니다. 동시에, 건강 인식 증가와 의료 인프라의 개선은 전 세계에서 백신 접종률을 높이고 있으며, 특히 그동안 의료 서비스를 충분히 받지 못했던 지역에서는 백신 접종률을 높이고 있습니다. 디지털 예방접종 추적 시스템 및 헬스케어 분야의 AI와 같은 기술 발전은 예방접종 캠페인의 도달 범위와 효율성을 향상시켜 보다 광범위하고 효과적인 커버리지를 보장하고 있습니다.
인체용 백신 시장의 성장 요인은 무엇인가?
인체용 백신 시장의 성장은 감염성 질환의 확산 증가, 전 세계에서 높아진 건강 인식, 백신 연구 및 개발의 발전 등 여러 요인에 의해 촉진되고 있습니다. 감염병 퇴치를 위한 정부 및 국제보건기구의 자금 지원과 투자 강화는 백신 분야의 확대와 혁신에 크게 기여하고 있습니다. 특히 COVID-19 팬데믹은 백신이 세계 보건 안보에서 차지하는 중요한 역할을 부각시키며 백신 개발 및 보급에 초점을 맞춘 전례 없는 민관 협력을 만들어냈습니다. 또한 고령화 및 감염에 대한 감수성을 높이는 만성질환 증가와 같은 인구통계학적 요인도 지속적인 백신 개발 및 접종의 필요성을 시사하고 있습니다. 이러한 추세는 종합적으로 현대 의학 및 공중 보건에서 백신의 중요한 역할을 강조하고, 이 필수적인 분야에 대한 지속적인 투자와 연구를 보장합니다.
부문 :
투여 경로(근육내·피하 투여, 경구 투여, 기타 투여 경로), 기술(결합 백신, 재조합 백신, 불활성화·서브유닛 백신, 약독생백신, 기타 기술)
조사 대상 기업의 예
ALK-Abello A/S
Altimmune, Inc.
Astellas Pharma Inc.
Bavarian Nordic A/S
Bharat Biotech
BiondVax Pharmaceuticals Ltd.
GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Janssen Pharmaceuticals Inc.
MedImmune
Mitsubishi Tanabe Pharma
Pfizer Inc.
Sanofi Pasteur SA
Seqirus
Serum Institute of India Pvt. Ltd.
SK BioScience
Takeda Pharmaceutical Company Limited
Zydus Cadila
AI 통합
검증된 전문가 컨텐츠와 AI 툴을 통해 시장 및 경쟁 정보 분석 방식을 혁신하고 있습니다.
Global Industry Analysts는 일반적인 LLM이나 산업 전문 SLM에 대한 쿼리 방식에 의존하는 대신, 전 세계 도메인 전문가들이 엄선한 컨텐츠 리포지토리를 구축했습니다. 여기에는 비디오 전사, 블로그, 검색엔진 조사, 그리고 방대한 양의 기업, 제품/서비스, 시장 데이터가 포함됩니다.
관세 영향 계수
이번 보고서에는 Global Industry Analysts가 예측한 본사 소재지, 생산기지, 수출입(완제품 및 OEM)에 따른 기업의 경쟁력 변화에 따라 지역 시장에 미치는 관세의 영향을 반영했습니다. 이러한 복잡하고 다면적인 시장 현실은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학을 통해 경쟁사들에게 영향을 미칠 것입니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Human Vaccines Market to Reach US$71.4 Billion by 2030
The global market for Human Vaccines estimated at US$46.9 Billion in the year 2024, is expected to reach US$71.4 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Intramuscular & Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$58.7 Billion by the end of the analysis period. Growth in the Oral Administration segment is estimated at 5.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$12.4 Billion While China is Forecast to Grow at 11.7% CAGR
The Human Vaccines market in the U.S. is estimated at US$12.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.8 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.
Global Human Vaccines Market - Key Trends and Drivers Summarized
Unveiling the Power of Human Vaccines: A Cornerstone of Modern Medicine
Human vaccines stand as one of the greatest achievements in public health, offering protection against a myriad of infectious diseases by training the immune system to recognize and combat pathogens. Comprising antigens that mimic disease-causing organisms, vaccines are crucial in preparing the immune system to fight diseases quickly and effectively. This mechanism has successfully led to the eradication and reduction of numerous life-threatening diseases, such as smallpox and polio, significantly lowering morbidity and mortality worldwide. Vaccines not only safeguard individuals but also contribute to herd immunity, preventing the spread of infections across communities and thereby securing population health globally.
Navigating New Frontiers: Innovations Enhancing Vaccine Efficacy and Safety
The landscape of vaccine technology is constantly evolving, incorporating novel methods that promise greater protection and safety. Traditional vaccine strategies, while effective, are now being enhanced with cutting-edge approaches like mRNA vaccines and recombinant technologies. These innovations offer precise targeting and rapid scalability, particularly highlighted by their role in addressing global challenges such as the COVID-19 pandemic swiftly. Furthermore, the development of adjuvants and improved delivery systems continues to revolutionize vaccine efficacy, broadening the horizons for combating more complex diseases and tailoring immunizations to diverse populations.
Emerging Trends Reshaping the Global Vaccine Sector
Global demographic and technological trends are reshaping the vaccine industry. The increase in international travel and urbanization elevates the risk of infectious disease transmission, amplifying the need for effective vaccination programs. Simultaneously, rising health consciousness and improved healthcare infrastructure are driving up vaccine uptake globally, especially in regions previously underserved. Technological advancements such as digital immunization tracking and AI in healthcare are also enhancing the reach and efficiency of vaccination campaigns, ensuring wider and more effective coverage.
What Drives the Growth in the Human Vaccines Market?
The growth in the human vaccines market is driven by several factors, including the increasing prevalence of infectious diseases, rising global health awareness, and advancements in vaccine research and development. Enhanced funding and investments by governments and global health organizations to eliminate infectious diseases contribute significantly to the expansion and innovation within the vaccine sector. The COVID-19 pandemic has particularly highlighted the critical role of vaccines in global health security, leading to unprecedented public and private partnerships focused on vaccine development and distribution. Moreover, demographic factors such as aging populations and the rise in chronic health conditions that increase susceptibility to infections necessitate continued vaccine development and uptake. Together, these dynamics underscore the vital role of vaccines in contemporary medicine and public health, ensuring ongoing investment and research in this essential field.
SCOPE OF STUDY:
The report analyzes the Human Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Administration Route (Intramuscular & Subcutaneous, Oral, Other Administration Routes); Technology (Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated, Other Technologies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 16 Featured) -
ALK - Abello A/S
Altimmune, Inc.
Astellas Pharma Inc.
Bavarian Nordic A/S
Bharat Biotech
BiondVax Pharmaceuticals Ltd.
GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Janssen Pharmaceuticals Inc.
MedImmune
Mitsubishi Tanabe Pharma
Pfizer Inc.
Sanofi Pasteur SA
Seqirus
Serum Institute of India Pvt. Ltd.
SK BioScience
Takeda Pharmaceutical Company Limited
Zydus Cadila
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
Global Economic Update
Human Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advances in Genetic and Recombinant Technology Expands Vaccine Efficacy
Demand Grows for Pediatric and Adult Vaccines Globally
Rising Awareness and Education About Vaccine Preventable Diseases
Integration of AI and Machine Learning in Vaccine Development
Innovations in Vaccine Delivery Systems and Adjuvants
Vaccination Programs on Public Health Systems Spur Vaccines Usage & Penetration Among Susceptible Populations
Emergence of New Pathogens Drives Demand for Novel Vaccines
Vaccine to Prevent HIV Still in the Pipeline
R&D Interest in Personalized Cancer Vaccines Gains Momentum
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Human Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Intramuscular & Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Intramuscular & Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Inactivated & Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Inactivated & Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: USA 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Canada 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Canada 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
JAPAN
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Japan 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Japan 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
CHINA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: China 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: China Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: China 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
EUROPE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Europe 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Europe 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Europe 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
FRANCE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: France 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: France Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: France 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
GERMANY
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Germany 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Germany 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Italy 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Italy 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
UNITED KINGDOM
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: UK 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: UK Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: UK 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Spain 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Spain 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Russia 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Russia 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Rest of Europe 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Rest of Europe 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Asia-Pacific 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Asia-Pacific 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Asia-Pacific 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
AUSTRALIA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Australia 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Australia 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
INDIA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: India 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: India Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: India 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: South Korea 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: South Korea 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
LATIN AMERICA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Latin America 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Latin America 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Latin America 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Argentina 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Argentina 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Brazil 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Brazil 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Mexico 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Mexico 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Rest of Latin America 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Rest of Latin America 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
MIDDLE EAST
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Middle East 15-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: Middle East 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: Middle East 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Iran 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Iran 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Israel 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Israel 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Saudi Arabia 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Saudi Arabia 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: UAE 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: UAE 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Rest of Middle East 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Rest of Middle East 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030
AFRICA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Human Vaccines by Administration Route - Intramuscular & Subcutaneous, Oral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Africa 15-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular & Subcutaneous, Oral and Other Administration Routes for the Years 2015, 2025 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Human Vaccines by Technology - Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Africa 15-Year Perspective for Human Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated and Other Technologies for the Years 2015, 2025 & 2030